Significant issues raised by meta-analyses of cancer mortality and dioxin exposure. by Starr, Thomas B
Scientific debate about the potential human
carcinogenicity of dioxin-like compounds has
been ongoing for nearly 25 years, and recent
meta-analyses of data from three occupation-
ally exposed cohorts have reached such differ-
ent conclusions that the debate is certain to
continue. The first meta-analysis [U.S.
Environmental Protection Agency (U.S. EPA)
2000] produced an upper-bound estimate of
the additional risk of death from any cancer of
approximately 10–3 per picogram per kilo-
gram per day for 2,3,7,8-tetrachlorodibenzo-
p-dioxin (TCDD) intake, which the U.S.
EPA generalized to all “dioxin-like” com-
pounds via toxic equivalency factors (TEFs).
This potency estimate implies that about
4,000 additional cancer deaths occur per year
in the United States solely from background
intake of dioxin-like compounds [about 1 pg
toxic equivalents (TEQ)/kg/day], 95% of
which comes from normal dietary sources,
and only 10% of which is due to TCDD
(U.S. EPA 2000).
Subsequently, in 2001, I (Starr 2001)
showed that the U.S. EPA’s model did not ﬁt
the data adequately because it failed to
account for a signiﬁcant baseline elevation of
all cancer mortality in the three cohorts; this
meta-analysis demonstrated that “these data
are entirely consistent with an intercept-only
model, a model that has no slope component
whatsoever in relation to estimated TCDD
body burden,” which implies zero additional
human cancer deaths from any and all expo-
sures to dioxin-like compounds. Finally,
Crump et al. (2003), using updated data for
the National Institute for Occupational Safety
and Health (NIOSH) cohort (Steenland et al.
1999, 2001), concluded that their meta-
analysis “provides some evidence that TEQ
exposures near current background levels are
carcinogenic.”
How is it possible for different investiga-
tors to reach such markedly different conclu-
sions from similar analyses of essentially the
same data? The answer lies in a)a   failure to
allow for causes of elevated cancer mortality
other than dioxin exposure; b) differences in
choices for a dose metric; c) selective use of dif-
ferent assumptions regarding the elimination
half-life of TCDD in humans; and d) selective
use of different assumptions regarding the
impact on cancer mortality of the most recent
15 years of exposure. Resolution of the dis-
parate conclusions will require detailed worker
exposure data for TCDD and for direct-acting
carcinogens, as well as a more general
dose–response model that adequately reﬂects
TCDD’s characteristics as a promoter.
Selection of a Dose Metric
Average TCDD body burden. The U.S. EPA
(2000) and I (Starr 2001) both employed
average TCDD body burden as the dose met-
ric. Fingerhut et al. (1991), in a study of the
NIOSH cohort (5,172 workers from 12 U.S.
plants), provided all cancer standardized mor-
tality ratios (SMRs) for four exposure dura-
tion categories—< 1, 1 to < 5, 5 to < 15, and
≥ 15 years—all with at least 20 years elapsed
since first exposure; SMRs [95% confidence
intervals (CIs)] for these categories are 102
(95% CI, 77–135), 165 (95% CI, 128–213),
138 (95% CI, 100–190), and 115 (95% CI,
73–181), respectively. Fingerhut et al. (1991)
observed a total of 162 cancer deaths through
the end of follow-up (31 December 1987)
among the 3,036 men included in this analy-
sis. The inverted dose response with increas-
ing exposure duration is worth noting.
Aylward et al. (1996) subsequently used
serum sample data for 253 workers from 2 of
the 12 NIOSH cohort plants to compute
average serum lipid TCDD concentrations
(temporally averaged from birth through
death or the end of follow-up). The sampled
workers received their last occupational expo-
sures to TCDD from 15 to 37 years before
the sampling date (Piacitelli et al. 2000),
necessitating a back-extrapolation from the
measured concentration on the sampling date
to earlier values assuming a 7.5-year elimina-
tion half-life for TCDD. Aylward et al.
(1996) also assumed constant exposures dur-
ing the occupational exposure period and a
5-ppt baseline serum lipid level before the
date of first occupational exposure. Group
means were estimated by averaging the values
for sampled workers in each of Fingerhut et
al.’s (1991) four duration categories.
Assuming a body fat content of 25% by
weight, the U.S. EPA (2000) calculated
equivalent average TCDD body burdens via
division by a 4-fold factor. Details of similar
average body burden calculations for the four
Hamburg cohort exposure categories (totaling
124 cancer deaths among 1,189 men; Flesch-
Janys et al. 1998) and the four BASF cohort
(BASF AG, Ludwigshafen, Germany) expo-
sure categories (totaling 31 cancer deaths
among 243 men; Ott and Zober 1996) have
been published previously (Starr 2001; U.S.
EPA 2000) and so are not repeated here.
Cumulative TCDD exposure score.
Steenland et al. (1999) extended follow-up
for a subset of the original NIOSH cohort (8
of 12 plants) by 6 years and used an exposure
assessment (Piacitelli et al. 2000) that quanti-
fied worker’s exposures during employment
with a score equal to the sum of products of
a) the concentration of TCDD in process
materials; b) the fraction of the day each
worker spent on each process; and c)a   “quali-
tative contact level” (0.01–1.5) based on the
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Research | Commentarypotential for inhalation of contaminated dust
and the amount of contamination thought to
reach exposed skin areas. A cumulative expo-
sure score was generated for the 3,538 workers
in their “exposure-level” cohort, which
included 256 cancer deaths, about 58% more
deaths than were included in Fingerhut et al.’s
(1991) earlier analysis by exposure duration.
Although Steenland et al. (1999) conducted
unlagged analyses with their cumulative expo-
sure score, they focused attention primarily on
results obtained when their cumulative expo-
sure scores were lagged by 15 years, in keeping
with a common epidemiologic practice of
assuming that cancer cannot result from expo-
sure until after a prolonged latency period. For
example, if workers’ cumulative exposure had
occurred solely during the most recent 15
years of follow-up, these workers were consid-
ered by Steenland et al. to be unexposed in
their lagged analyses, and their person-years of
experience were allocated to the lowest of their
seven exposure categories, irrespective of how
great the workers’ actual cumulative exposure
scores may have been.
Among workers who were assigned to
Steenland et al.’s (1999) lowest exposure cate-
gory solely by virtue of the 15-year lag assump-
tion, there were 40.2 cancer deaths expected,
but only 33 were observed, yielding an SMR of
82 (95% CI, 58–115) among these men
defined by assumption to have little or no
exposure [expected deaths calculated from data
in footnote to Steenland et al.’s Table 2
(Steenland et al. 1999)]. The remaining 34
cancer deaths in Steenland et al.’s lowest septile
must have occurred among men with truly low
scores even without the 15-year lag assump-
tion, and the all-cancer SMR among these men
was 34/24.1 = 121 (95% CI, 101–197) [also
calculated from Steenland et al.’s Table 2 data;
(Steenland et al. 1999)], which is signiﬁcantly
elevated (p < 0.025).
Steenland et al.’s reported SMR of 98 for
their lowest cumulative exposure septile
(Steenland et al. 1999) is thus a weighted
average of the significantly elevated SMR
(121) among men with truly low cumulative
exposures and the depressed SMR (82)
among men who actually had higher cumula-
tive exposure scores but were shifted down-
ward, via the 15-year lag assumption, from
higher septiles into the lowest septile. The net
result of the 15-year lag assumption was thus
to depress the SMR in their lowest exposure
score septile and simultaneously elevate the
SMRs in higher septiles. This produces an
artifactual strengthening of the dose–response
relationship relative to that reported previ-
ously by Fingerhut et al. (1991). The 6 years
of additional follow-up included by Steenland
et al. (1999) may also contribute to the appar-
ent strengthening of the relationship, but it is
impossible to determine the extent to which
this occurred without access to individual
worker data.
Cumulative serum lipid TCDD concen-
tration. Steenland et al. (2001) subsequently
took Aylward et al.’s (1996) approach to back-
extrapolate measured TCDD levels for 170
workers from one plant to levels expected on
the workers’ dates of last exposure. However,
Steenland et al. used the 8.7-year elimination
half-life reported by Michalek et al. (1996), in
contrast to the 7.5-year half-life employed by
Aylward et al. (1996), the 7.2-year value esti-
mated by Flesch-Janys et al. (1996) for the
Hamburg cohort, the 7.0-year value employed
by Ott et al. (1993) for the BASF cohort, or
the 7.6-year half-life reported more recently by
Michalek and Tripathi (1999).
The differences in these estimates may
appear small, but the impact of Steenland et
al.’s (2001) use of a longer half-life is not triv-
ial. Because the back-extrapolations ranged
over periods of 15–37 years, Aylward et al.’s
(1996) back-extrapolated values were between
2(15/7.5) = 4 and 2(37/7.5) = 30.6 times larger
than the measured serum levels, whereas
Steenland et al.’s (2001) back-extrapolated
values were between only 2(15/8.7) = 3.3 and
2(37/8.7) = 19.1 times larger, that is, about
18–38% smaller than Aylward et al.’s values.
This produces a corresponding inflation of
the apparent carcinogenic potency of TCDD,
but more important, as discussed below, its
use only for the NIOSH cohort in Crump et
al.’s meta-analysis (Crump et al. 2003) con-
tributes to a downward shift of the NIOSH
data points on the exposure scale relative to
those for the Hamburg and BASF cohorts.
Steenland et al. (2001) calibrated their
cumulative exposure scores at the time of last
exposure against the back-extrapolated serum
lipid levels by linear regression. For the 170
workers with measured TCDD levels greater
than 10 ppt, the Spearman correlation between
their cumulative exposure scores and the back-
extrapolated lipid levels was highly signiﬁcant
(rho = 0.65, p = 0.0001). However, Fingerhut
et al. (1991) computed Pearson’s product-
moment correlations between the logarithm of
exposure duration and the logarithm of the
measured serum levels for 253 workers, and
this correlation was comparable and also highly
signiﬁcant (r = 0.72, p < 0.0001).
Furthermore, when Piacitelli et al. (2000)
calculated the Spearman correlation between
exposure duration and back-extrapolated serum
lipid TCDD levels, they obtained 0.74, higher
still than the value for their detailed cumulative
exposure scores, and they acknowledged that
the scores “did not improve upon duration of
exposure as an estimate of exposure level at this
plant….” It is thus arguable whether Steenland
et al.’s (2001) extensive efforts to develop a dose
metric superior to Fingerhut et al.’s (1991)
simpler exposure duration were successful.
Cumulative serum lipid TEQ concentra-
tion. Crump et al. (2003) chose cumulative
serum lipid TEQ concentration, lagged 15
years or not, depending on the cohort, as their
dose metric. For the SMR data from Steenland
et al. (1999), Crump et al. used the cumulative
serum lipid TCDD concentration, as predicted
by Steenland et al.’s (2001) linear regression,
but lagged 15 years. It is important to note
here that Steenland et al. (1999) purposefully
excluded from their analysis 727 TCDD-
exposed workers that had been included in
Fingerhut et al.’s (1991) original analysis;
Steenland et al.’s stated reason was that 
727 workers with exposure to both penta-
chlorophenol and TCDD were eliminated to
avoid possible confounding of any TCDD effects
by pentachlorophenol. Pentachlorophenol is cont-
aminated with higher chlorinated dioxins. These
dioxins and TCDD are thought to act similarly
with regard to the Ah receptor and gene expres-
sion, although they are considered less toxic.
Ironically, this “similarity of action” is the
reason Crump et al. (2003) added 2,700 ppt-
years of non-TCDD background TEQ to
their dose metric for the NIOSH cohort (and
3,000 ppt of TEQ to the Hamburg and
BASF cohort values as well) before conduct-
ing their trend analyses (i.e., because they pre-
sumed that non-TCDD congeners should be
included after taking account of relative
potency differences via TEFs). The assump-
tion that polychlorinated dibenzo-p-dioxins
(PCDDs), polychlorinated dibenzofurans
(PCDFs), and the dioxin-like coplanar poly-
chlorinated biphenyls can be combined, using
TEFs, into a single exposure metric (TEQ)
suitable for use in human cancer risk assess-
ment has been embraced by the U.S. EPA
(2000) and the World Health Organization
(Van den Berg et al. 1998), among others,
but this simplistic approach to complex mix-
tures of dioxin-like compounds is not without
controversy (e.g., Starr et al. 1997, 1999).
For the Hamburg cohort, Crump et al.
(2003) selected SMR data for quartiles of
unlagged cumulative serum lipid TEQ con-
centration above background as provided in
Table 6 of Flesch-Janys et al. (1998). Because
Crump et al.’s dose metric for this cohort was
estimated with a 7.2-year half-life for TCDD
(Flesch-Janys et al. 1996) and no lag, whereas
their NIOSH dose metric was estimated with
an 8.7-year half-life and a lag of 15 years,
there is a substantial downward shift of the
NIOSH cohort’s data points on the cumula-
tive exposure scale relative to those for the
Hamburg cohort.
To illustrate, suppose that a Hamburg
cohort worker had a measured serum TCDD
concentration of 1,000 ppt but had not been
occupationally exposed during the 15 years
immediately preceding the measurement.
Then the contribution from those 15 years to
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measurement would be 33,633 ppt-years using
Flesch-Janys et al.’s 7.2-year TCDD half-life
(Flesch-Janys et al. 1996) and no lag. For a
worker from the NIOSH cohort with the same
measured concentration, Steenland et al.’s 8.7-
year half-life (Steenland et al. 2001) gives a
corresponding contribution to cumulative
TCDD exposure of only 28,916 ppt-years,
about 4,717 ppt-years smaller. However, with
the 15-year lag assumption, the contribution
to this worker’s cumulative exposure from the
15-year premeasurement period would be
identically zero. The difference is thus 33,633
ppt-years, a huge difference in the relative
placement of the NIOSH and Hamburg
cohort workers on Crump et al.’s cumulative
TEQ exposure scale (Crump et al. 2003).
Three of the four Hamburg cohort data
points fall more than 4-fold below that for the
lowest data point from the NIOSH cohort in
both the U.S. EPA’s (2000) and my (Starr
2001) meta-analyses, but the two lowest
NIOSH cohort data points from Crump et
al.’s (2003) meta-analysis are lower than all of
the remaining data points used in their meta-
analysis. Although Crump et al. (2003) specu-
lated that “results based on cumulative exposure
lagged 15 years should not differ greatly from
those based on unlagged exposure,” their
selective use of exposure lagged by 15 years
only for the NIOSH cohort creates artificial
intercohort differences in cumulative TCDD
(and TEQ) exposure that are not trivial.
For the BASF cohort of 243 men with 31
cancer deaths (Ott and Zober 1996), the U.S.
EPA (2000), Starr (2001), and Crump et al.
(2003) all employed SMR data for four cate-
gories of total TCDD intake, expressed in
micrograms per kilogram of body weight:
< 0.1, 0.1–0.99, 1.0–1.99, and ≥ 2.00. Because
exposure in this cohort occurred over a very
short time after an uncontrolled reactor release
on 17 November 1953, the temporal exposure
pattern is essentially a pulsatile spike followed
by an extended elimination phase. For these
data, all three meta-analyses employed a
TCDD half-life of 7.0 years, as previously
reported by Ott et al. (1993), and unlagged
dose metrics. When the 8.7-year half-life and
15-year lag Crump et al. (2003) used for the
NIOSH cohort are coupled with the 7.0-year
half-life and no lag they used for the BASF
cohort, the joint effect is again a substantial
downward shift of the NIOSH cohort’s data
points relative to those from the BASF cohort,
on the cumulative exposure scale.
TCDD or TEQ? Finally, we come to the
critical issue of whether a dose metric based on
TEQ is preferable to one based solely on
TCDD. TCDD is the only congener to which
workers were exposed in the NIOSH sub-
cohort (Steenland et al. 1999, 2001) and the
BASF cohort (Ott and Zober 1996) because
Steenland et al. had purposefully excluded
from their update 727 workers who were
exposed not only to TCDD but also to pen-
tachlorophenol due to the latter material’s
contamination with higher chlorinated diox-
ins. Furthermore, in the Hamburg cohort
(Flesch-Janys et al. 1998), the only one whose
workers had any significant occupational
exposure to non-TCDD congeners, there is
no substantive evidence that TEQ provides a
better dose metric than TCDD. Indeed, the
evidence is quite to the contrary.
Flesch-Janys et al. (1998) conducted trend
tests of all cancer mortality versus either cumu-
lative lipid TCDD concentration above back-
ground (SMRs were 124, 134, 134, and 173
in order of increasing exposure) or equivalent
TEQ concentration above background (SMRs
were 107, 164, 133, and 164 in order of
increasing TEQ exposure): only trend versus
TCDD was signiﬁcant (p = 0.01); trend versus
TEQ was totally unremarkable (p = 0.48).
Flesch-Janys et al. also conducted trend tests
on lung, hematopoietic, and lymphoid cancer
and mortality from all causes; in none of these
cases was there a signiﬁcant trend with TEQ.
There is thus no compelling evidence in
the three occupational cohorts to support
Crump et al.’s (2003) selection of TEQ as the
basis for a dose metric. Yet Crump et al. con-
cluded from their analysis that “TEQ expo-
sures within roughly 3-fold of current
background levels may be carcinogenic.” This
conclusion is not justified by the data or
Crump et al.’s meta-analysis. To legitimately
implicate cumulative serum lipid TEQ con-
centration as a potential cause of increased
human cancer mortality, it would be neces-
sary to show that a dose–response analysis
using TEQ produced a model with signifi-
cantly greater explanatory power than one
based solely on the TCDD component of
exposure. However, Crump et al. do not
appear to have explored this possibility.
Had Crump et al. (2003) conducted such
an incremental meta-analysis, they would
have discovered that a linear model with
cumulative TCDD exposure actually ﬁts the
three cohort data sets somewhat better than
the very same model with cumulative TEQ
exposure, although the difference in log-likeli-
hoods for the two models is small. The evi-
dence from these three occupational cohorts
thus indicates nothing at all about the human
carcinogenicity of non-TCDD congeners, and
this evaluation is entirely consistent with the
International Agency for Research on Cancer’s
1997 assessment of the evidence regarding
these substances (McGregor et al. 1998): 
Other PCDDs [polychlorinated dibenzo-p-dioxins]
are not classifiable as to their carcinogenicity to
humans (group 3). Dibenzo-p-dioxin is not classiﬁ-
able as to its carcinogenicity to humans (group 3).
PCDFs [polychlorinated dibenzofurans] are not
classifiable as to their carcinogenicity to humans
(group 3).
The evidence regarding the potential carcino-
genicity of TEQ is simply inadequate.
A Dose Metric and
Dose–Response Model
Appropriate for TCDD
The dose–response models used by the U.S.
EPA (2000), Starr (2001), and Crump et al.
(2003), in their meta-analyses relate increments
in cancer mortality to the various dose metrics
discussed previously in proportional fashion,
that is, linearly, consistent with the classical
mechanistic concepts (e.g., Whittemore and
Keller 1978) of how direct-acting carcinogens
operate. Such models are predicated on the
assumption that the carcinogenic moiety inter-
acts biochemically with the DNA of susceptible
cells to cause irreversible and cumulative DNA
damage that accrues through time, leading
eventually to the production of initiated cells
and, ultimately, to malignancy. However, this
model is not an appropriate one for TCDD.
The wealth of data collected on the car-
cinogenicity of TCDD in laboratory animals
points compellingly toward a promotional
mechanism of action, whereby cells previously
initiated, either spontaneously or by exposure
to direct-acting carcinogens, are conferred a
selective growth advantage by subsequent
exposure to the “promoting” agent, thereby
inducing a rapid and sustained clonal expan-
sion of the initiated cell population (e.g.,
Berenblum and Shubik 1947; Emmelot and
Scherer 1980; Farber 1982). One hallmark of
substances classified as “promoters” is the
absence of DNA reactivity and mutagenicity in
short term in vitro test systems, and this has
been demonstrated for TCDD (U.S. EPA
2000). Another is the requirement for sus-
tained exposure to the promoting agent to
maintain the selective growth advantage of the
initiated cell population for an extended time.
For example, early cessation of exposure to
phenobarbitol has been shown to result in the
spontaneous regression of preneoplastic lesions
induced by the direct-acting carcinogen
N-nitrosomorpholine (Bursch et al. 1984).
A third hallmark of promoters is that the
“promoting” exposure must occur after the
direct-acting carcinogen exposures. Prior
exposures to promoting agents are simply not
effective at enhancing carcinogenesis, and a
delay or lag between the initiating exposures
and subsequent promoting exposures may
attenuate the promotional effect, but it is not
eliminated. This characteristic of promoters
has also been demonstrated with phenobarbi-
tol: only 20% fewer altered hepatic foci were
produced when the time interval between ini-
tiation by diethylnitrosamine and the onset of
a 6-month period of promotion by phenobar-
bitol was increased from 1 day to 11 months
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exposures to promoting agents therefore appear
to be the most important ones. Finally, it is
worth nothing that the U.S. EPA’s Science
Advisory Board Dioxin Reassessment Review
Committee called attention to the fact that
TCDD appeared to be a promoter and would
therefore require a different kind of dose–
response model that reﬂected the unique mech-
anistic properties of a promoter (Paustenbach
2002; U.S. EPA 2001).
In the present context, a dose–response
model appropriate for TCDD would of neces-
sity require both direct-acting carcinogen and
promoting components and a corresponding
multidimensional dose metric. The promoting
component of the model would depend on
TCDD concentration, and the direct-acting
carcinogen component would need to accu-
rately reflect workers’ previous exposures to
multiple direct-acting carcinogens in the
workplace as well as elsewhere. Sadly, little
attention has been paid to this multiple expo-
sure problem despite its high rate of occur-
rence in occupational cohorts.
For example, there is clear evidence of
exposure to 4-aminobiphenyl in the NIOSH
cohort (Collins et al. 1992), and to tobacco
smoke in the NIOSH (Fingerhut et al. 1991)
and BASF (Ott and Zober 1996) cohorts. Yet
none of the meta-analyses discussed herein
accounted explicitly for the potential effects
of such exposures on all cancer mortality.
Indeed, in most of the studies discussed
herein (Flesch-Janys et al. 1998; Ott and
Zober 1996; Steenland et al. 1999, 2001;
U.S. EPA 2000), all of the excess cancer mor-
tality reported in the three occupational
cohorts has been attributed to the workers’
TCDD (or TEQ) exposures. Only Crump et
al.’s (2003) and my (Starr 2001) meta-analy-
ses included a variable intercept term that
allows for increased all-cancer mortality even
in the absence of exposure to dioxin-like com-
pounds. Commenting on the 32% increase in
baseline all-cancer mortality reported in my
meta-analysis, I (Starr 2001) stated that 
The challenge is to discover the true cause of this
significant excess in all cancer mortality, as it
appears to be attributable to factors other than the
workers’ TCDD body burdens.
The direct-acting carcinogen and pro-
moting components of a dose–response
model appropriate for TCDD would also
need to be weighted differentially in time;
that is, TCDD exposures preceding direct-
acting carcinogen exposures would have little
or no impact on the likelihood of carcino-
genicity, whereas subsequent, and even the
most recent, TCDD exposures would need
to figure prominently in quantifying the
impact of TCDD on carcinogenesis. This lat-
ter property of a promoter, namely, that the
most recent exposures are possibly the most
important (e.g. Xu et al. 1990), is completely
at odds with Steenland et al.’s decision
(Steenland et al. 1999, 2001), embraced sub-
sequently by Crump et al. (2003), to assign
zero weight to the NIOSH cohort workers’
most recent 15 years of TCDD exposure via
their 15-year lag assumption.
Finally, the direct-acting carcinogen and
promoting components of this dose–response
model would have to be multiplicative; that
is, risk would be proportional to the product
of these two components, so that carcino-
genicity would not be predicted unless there
were appropriately sequenced exposures of
sufficient intensity and duration to both
direct-acting carcinogens and TCDD.
Conclusion
In their concluding remarks, Crump et al.
(2003) commented that they do not see a clear
choice between results from their meta-analysis
and the considerably more conservative
NIOSH subcohort analysis by Steenland et al.
(2001), and suggested that additional research
might be warranted if the policy implications
of the predicted risks are large. I agree that
additional research on the potential carcino-
genicity of human exposures to TCDD and
other dioxin-like compounds is warranted, but
only if detailed exposure data for individual
workers are made available to all interested
parties and the scope of the research is enlarged
to consider both a) exposure to direct-acting
carcinogens as well as TCDD and b) dose–
response models that are mechanistically
appropriate for a promoter such as TCDD.
Without detailed exposure histories for
individual workers, it is not possible to assess
objectively whether Steenland et al.’s (2001)
sophisticated TCDD exposure reconstruction
is in any way superior to Fingerhut et al.’s
(1991) much simpler dose metric of TCDD
exposure duration. As noted above for the
workers from the NIOSH cohort with mea-
sured serum concentrations, exposure dura-
tion appears actually to be somewhat more
tightly correlated with the measured TCDD
levels than is Steenland et al.’s (2001) cumu-
lative TCDD exposure score, but differences
due to the additional years of follow-up
included in Steenland et al.’s (2001) analysis
must also be considered.
Interestingly, when Adami et al. (2000)
split out the all-cancer mortality for the 6 addi-
tional years of follow-up that had not been
included in Fingerhut et al.’s original report
(Fingerhut et al. 1991), the all-cancer SMR
(108) was not signiﬁcant and was reduced rela-
tive to Fingerhut et al.’s estimate of 115, yet
the dose–response appears far stronger in
Steenland et al.’s (2001) update analyses than
it does in Fingerhut et al.’s report (Fingerhut et
al. 1991). Superﬁcially at least, these early and
later results appear inconsistent with one
another, but I have shown how at least some
of the strengthening of the apparent dose
response in the more recent reports is artifac-
tual and attributable to Steenland et al.’s
(2001) application of a 15-year lag assumption
and longer elimination half-life in their analysis
of the NIOSH cohort.
We also conclude that Crump et al.’s
extrapolation (Crump et al. 2003) from
Steenland et al.’s TCDD analyses (Steenland
et al. 1999, 2001) to one based on TEQ is
unjustified and overreaching because neither
the epidemiologic data nor their meta-analysis
of it support the inference that TEQ expo-
sures close to background are likely to be car-
cinogenic to humans (Flesch-Janys et al. 1998;
McGregor et al. 1998). Their extrapolation
from TCDD to TEQ is especially troubling
because it raises unnecessary concerns about
the safety of our food supply.
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